Detalles de la búsqueda
1.
Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets.
Hum Psychopharmacol
; 22(5): 307-14, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17487933
2.
Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Curr Med Res Opin
; 22(12): 2557-66, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17166338
3.
A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Can J Clin Pharmacol
; 13(1): e50-62, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16456216
Resultados
1 -
3
de 3
1
Próxima >
>>